Tags

Type your tag names separated by a space and hit enter

Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution.
Am J Clin Pathol. 2002 Feb; 117(2):188-93.AJ

Abstract

We performed immunohistochemical analysis for KIT in 365 soft tissue sarcomas. Most tumors evaluated were completely negative for KIT, including all cases of leiomyosarcoma, rhabdomyosarcoma, myxofibrosarcoma, liposarcoma, solitary fibrous tumor, synovial sarcoma, dermatofibrosarcoma protuberans, schwannoma, malignant peripheral nerve sheath tumor, clear cell sarcoma, low-grade endometrial stromal sarcoma, and follicular dendritic cell sarcoma. Tumors showing occasional immunoreactivity for KIT included extraskeletal myxoid chondrosarcoma (2/20), Ewing sarcoma/malignant primitive peripheral neuroectodermal tumor (4/20), melanotic schwannoma (3/5), metastatic melanoma (4/20), and angiosarcoma (5/20). In most cases, staining for KIT was focal. Rare tumor cells showing KIT positivity were identified in a small number of other tumors. This study demonstrates very limited expression of KIT in soft tissue tumors other than gastrointestinal stromal tumors and underscores the discriminatory value of KIT immunohistochemical analysis for differential diagnosis. As some of these findings differ markedly from previous reports, it is evident again that variations in immunohistochemical technique can lead to major discrepancies in positive staining. Since treatment eligibility for selective tyrosine kinase inhibitors such as STI571 hinges on positive immunostaining, standardization and reproducibility of meaningful results are critically important.

Authors+Show Affiliations

Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

11865845

Citation

Hornick, Jason L., and Christopher D M. Fletcher. "Immunohistochemical Staining for KIT (CD117) in Soft Tissue Sarcomas Is Very Limited in Distribution." American Journal of Clinical Pathology, vol. 117, no. 2, 2002, pp. 188-93.
Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol. 2002;117(2):188-93.
Hornick, J. L., & Fletcher, C. D. (2002). Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. American Journal of Clinical Pathology, 117(2), 188-93.
Hornick JL, Fletcher CD. Immunohistochemical Staining for KIT (CD117) in Soft Tissue Sarcomas Is Very Limited in Distribution. Am J Clin Pathol. 2002;117(2):188-93. PubMed PMID: 11865845.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. AU - Hornick,Jason L, AU - Fletcher,Christopher D M, PY - 2002/2/28/pubmed PY - 2002/3/2/medline PY - 2002/2/28/entrez SP - 188 EP - 93 JF - American journal of clinical pathology JO - Am. J. Clin. Pathol. VL - 117 IS - 2 N2 - We performed immunohistochemical analysis for KIT in 365 soft tissue sarcomas. Most tumors evaluated were completely negative for KIT, including all cases of leiomyosarcoma, rhabdomyosarcoma, myxofibrosarcoma, liposarcoma, solitary fibrous tumor, synovial sarcoma, dermatofibrosarcoma protuberans, schwannoma, malignant peripheral nerve sheath tumor, clear cell sarcoma, low-grade endometrial stromal sarcoma, and follicular dendritic cell sarcoma. Tumors showing occasional immunoreactivity for KIT included extraskeletal myxoid chondrosarcoma (2/20), Ewing sarcoma/malignant primitive peripheral neuroectodermal tumor (4/20), melanotic schwannoma (3/5), metastatic melanoma (4/20), and angiosarcoma (5/20). In most cases, staining for KIT was focal. Rare tumor cells showing KIT positivity were identified in a small number of other tumors. This study demonstrates very limited expression of KIT in soft tissue tumors other than gastrointestinal stromal tumors and underscores the discriminatory value of KIT immunohistochemical analysis for differential diagnosis. As some of these findings differ markedly from previous reports, it is evident again that variations in immunohistochemical technique can lead to major discrepancies in positive staining. Since treatment eligibility for selective tyrosine kinase inhibitors such as STI571 hinges on positive immunostaining, standardization and reproducibility of meaningful results are critically important. SN - 0002-9173 UR - https://www.unboundmedicine.com/medline/citation/11865845/Immunohistochemical_staining_for_KIT__CD117__in_soft_tissue_sarcomas_is_very_limited_in_distribution_ L2 - https://academic.oup.com/ajcp/article-lookup/doi/10.1309/LX9U-F7P0-UWDH-8Y6R DB - PRIME DP - Unbound Medicine ER -